Published in Dig Dis Sci on August 17, 2007
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) | NCT00788918
Insulin resistance and Alzheimer's disease. BMB Rep (2009) 1.49
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2012) 1.48
PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis. Aliment Pharmacol Ther (2011) 1.22
Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21
Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol (2013) 1.21
Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol (2008) 1.21
Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev (2009) 1.17
Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc (2011) 1.15
Quantitative diffusion tensor imaging tractography metrics are associated with cognitive performance among HIV-infected patients. Brain Imaging Behav (2010) 1.01
The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids. Int J Environ Res Public Health (2009) 1.00
Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis (2016) 0.96
Discounting of delayed rewards and executive dysfunction in individuals infected with hepatitis C. J Clin Exp Neuropsychol (2010) 0.93
Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) (2012) 0.92
Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat Mon (2013) 0.92
Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis (2012) 0.91
Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults. AIDS Care (2012) 0.85
Alcohol, insulin resistance and the liver-brain axis. J Gastroenterol Hepatol (2012) 0.83
Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART. J Neurovirol (2014) 0.82
Intra-individual variability across neurocognitive domains in chronic hepatitis C infection: elevated dispersion is associated with serostatus and unemployment risk. Clin Neuropsychol (2012) 0.81
Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. Am J Gastroenterol (2010) 0.80
Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol (2014) 0.80
Patients with hepatitis C infection and normal liver function: an evaluation of cognitive function. Postgrad Med J (2013) 0.79
Psychosocial correlates of alcohol use and reduction for individuals with hepatitis C. J Stud Alcohol Drugs (2011) 0.79
Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China. Asia Pac Psychiatry (2012) 0.78
Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. Panminerva Med (2012) 0.77
Protective effects of higher cognitive reserve for neuropsychological and daily functioning among individuals infected with hepatitis C. J Neurovirol (2013) 0.76
Hepatitis C virus antibody titers associated with cognitive dysfunction in an asymptomatic community-based sample. J Clin Exp Neuropsychol (2016) 0.75
Association of Alzhemier's disease with hepatitis C among patients with bipolar disorder. PLoS One (2017) 0.75
Hepatitis C Virus Infection in the Older Patient. Infect Dis Clin North Am (2017) 0.75
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology (2002) 7.53
The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc (1995) 5.38
Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS (2004) 5.04
Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry (1990) 4.08
The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology (2000) 3.53
Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry (2000) 2.96
Cytokines and cognition--the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc (2002) 2.79
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology (1999) 2.67
Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology (2004) 2.54
Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology (2005) 2.45
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology (2002) 2.26
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18
Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer (2005) 2.09
Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol (2002) 2.05
Executive function, working memory, and medication adherence among older adults. J Gerontol B Psychol Sci Soc Sci (2006) 2.04
Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol (2003) 2.04
Evidence for a cerebral effect of the hepatitis C virus. Lancet (2001) 1.90
Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology (1996) 1.89
A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation (2004) 1.87
Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry (2005) 1.80
Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol (2004) 1.76
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology (1995) 1.71
Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry (1995) 1.64
Neuropsychological impairment in patients with chronic hepatitis C. Hepatology (2002) 1.62
Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals. Psychopharmacology (Berl) (2005) 1.61
Understanding hepatitis C. Am J Manag Care (2004) 1.58
The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS (2005) 1.55
Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry (2001) 1.55
Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology (2005) 1.49
Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology (1999) 1.49
Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology (2002) 1.47
Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune systems. J Neuroimmunol (2006) 1.44
Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. J Virol (1999) 1.42
Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol (2002) 1.42
Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc (2003) 1.39
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection (2004) 1.37
Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) (2000) 1.35
Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res (2000) 1.32
Neurocognition in depression: patients on and off medication versus healthy comparison subjects. J Neuropsychiatry Clin Neurosci (2006) 1.28
Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol (2002) 1.28
Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry (1994) 1.27
The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS (2005) 1.26
A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS (2005) 1.25
The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci (2005) 1.25
Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J Neurosci Res (2001) 1.24
Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med (2001) 1.20
Hepatitis C virus infection. Clin Microbiol Infect (2005) 1.19
Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol (2002) 1.19
Stroop performance in drug users classified by HIV and hepatitis C virus serostatus. J Int Neuropsychol Soc (2004) 1.19
Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology (1999) 1.19
Differential production of and migratory response to beta chemokines by human microglia and astrocytes. J Infect Dis (1997) 1.18
Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry (2005) 1.18
Neuropsychological functioning in a cohort of HIV- and hepatitis C virus-infected women. AIDS (2005) 1.17
Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics (2000) 1.16
Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol (1998) 1.16
Emerging evidence of hepatitis C virus neuroinvasion. AIDS (2005) 1.14
Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients. Clin Exp Immunol (1996) 1.13
Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages. Blood (2004) 1.13
Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat (2003) 1.13
Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics (2001) 1.12
Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-alpha and interleukin 8. J Gen Virol (2004) 1.09
Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS (2005) 1.08
In vitro infection of peripheral blood mononuclear cells by hepatitis C virus. J Gen Virol (1995) 1.06
Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res (2001) 1.06
Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry (2006) 1.05
Study of the infection of human blood derived monocyte/macrophages with hepatitis C virus in vitro. J Med Virol (2001) 1.04
Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol (2006) 1.01
Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol (2001) 0.99
Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr (2004) 0.99
Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA (1984) 0.99
Detection and quasispecies analysis of hepatitis C virus in the cerebrospinal fluid of infected patients. J Neurovirol (1999) 0.99
Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol (2005) 0.98
Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users. J Int Neuropsychol Soc (2004) 0.98
Fatigue, depression and chronic hepatitis C infection. Psychol Med (2002) 0.98
Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc (2005) 0.97
Lesions of the dorsomedial nucleus of the thalamus, medial prefrontal cortex and pedunculopontine nucleus: effects on locomotor activity mediated by nucleus accumbens-ventral pallidal circuitry. Brain Res (1987) 0.95
Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients. J Med Virol (1997) 0.95
Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry (2002) 0.92
Abnormalities of prepulse inhibition do not depend on blink reflex excitability: a study in Parkinson's disease and Huntington's disease. Clin Neurophysiol (2004) 0.91
Persistent cognitive deficits in community-treated alcoholic men and women volunteering for research: limited contribution from psychiatric comorbidity. J Stud Alcohol (2005) 0.91
Central nervous system involvement in hepatitis C virus infection. Metab Brain Dis (2004) 0.90
Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection. AIDS (2005) 0.89
Reduced quality of life in hepatitis C--is it all in the head? J Hepatol (2002) 0.88
Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther (2005) 0.88
Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. J Affect Disord (2005) 0.87
Penetration of neurotrophins and cytokines across the blood-brain/blood-spinal cord barrier. Adv Drug Deliv Rev (1999) 0.87
T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. Hepatology (2003) 0.86
Effects of interferon alpha on performance in man: a preliminary report. Psychopharmacology (Berl) (1988) 0.85
Prepulse inhibition in patients with non-psychotic major depressive disorder. J Affect Disord (2004) 0.84
Alterations of quantitative EEG and mini-mental state examination in interferon-alpha-treated hepatitis C. Eur Neurol (2002) 0.84
Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. Psychosomatics (2004) 0.83
Differential display analysis of gene expression in brains from hepatitis C-infected patients. AIDS (2005) 0.82
Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol (1998) 0.82
Use of cytokines in infection. Expert Opin Emerg Drugs (2004) 0.80
Blinded, prospective, and serial evaluation by quantitative-EEG in interferon-alpha-treated hepatitis-C. Acta Neurol Scand (1999) 0.80
Human recombinant tumor necrosis factor and interferon affect the activity of neurons in the organum vasculosum laminae terminalis. Brain Res (1991) 0.80
Contribution of functional neuroimaging to understanding neuropsychiatric side effects of interferon in hepatitis C. Psychosomatics (2004) 0.80
Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology (2006) 2.23
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol (2003) 1.83
Neuropsychological impairment in patients with chronic hepatitis C. Hepatology (2002) 1.62
Neuropsychiatric aspects of coinfection with HIV and hepatitis C virus. AIDS Read (2008) 1.46
Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc (2003) 1.39
Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett (2004) 1.05
Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS (2005) 1.04
Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol (2007) 1.02
Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci (2007) 1.01
Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc (2005) 0.97
Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. J Clin Exp Neuropsychol (2008) 0.96
Biopsychosocial predictors of fatigue in chronic hepatitis C. J Psychosom Res (2005) 0.93
Utility of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in patients with end-stage liver disease awaiting liver transplant. Arch Clin Neuropsychol (2007) 0.91
Implications of hepatitis C virus infection for behavioral symptoms and activities of daily living. J Clin Exp Neuropsychol (2010) 0.88
Main portal vein access in transjugular intrahepatic portosystemic shunt procedures: use of three-dimensional ultrasound to ensure safety. J Vasc Interv Radiol (2002) 0.86
The Pillbox Test: an ecological measure of executive functioning and estimate of medication management abilities. Arch Clin Neuropsychol (2013) 0.83
Neuropsychiatric complications of interferons: classification, neurochemical bases, and management. Ann Clin Psychiatry (2007) 0.82
No effect of PTSD and other psychiatric disorders on cognitive functioning in veterans with mild TBI. Clin Neuropsychol (2011) 0.81
Utility of the trail making test in the assessment of malingering in a sample of mild traumatic brain injury litigants. Clin Neuropsychol (2003) 0.81
Information processing following mild head injury. Arch Clin Neuropsychol (2006) 0.80
Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin. Am J Health Syst Pharm (2009) 0.78
Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation. J Clin Gastroenterol (2005) 0.78
Delivery of radiofrequency ablation probes to the targeted liver malignancy: using all the players on the field. J Vasc Interv Radiol (2002) 0.77
Role of Sleep Disturbance in Chronic Hepatitis C Infection. Curr Hepat Rep (2010) 0.77
Neuropsychological and emotional changes during simulated microgravity: effects of triiodothyronine alendronate, and testosterone. Arch Clin Neuropsychol (2004) 0.76
Assessment and usefulness of clinical scales for semiquantification of overt hepatic encephalopathy. Clin Liver Dis (2012) 0.76
The influence of ethnicity on Symbol Digit Modalities Test performance: an analysis of a multi-ethnic college and hepatitis C patient sample. Appl Neuropsychol (2007) 0.75
The Recognition Memory Test Examination of ethnic differences and norm validity. Arch Clin Neuropsychol (2003) 0.75
Complex partial seizure symptom endorsement in individuals with a history of head injury. Arch Clin Neuropsychol (2006) 0.75
WAIS-IV visual puzzles in a mixed clinical sample. Clin Neuropsychol (2012) 0.75
Comparing two methods of delivering neuropsychological feedback. Arch Clin Neuropsychol (2013) 0.75